Reposted by Jota
Revlimid has its origin in a pill that cost patients $7.50 each.
Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture.
(Published May 2025)
Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture.
(Published May 2025)
The Price of Remission: This Cancer Drug Saves Lives — but Costs a Fortune. I Wanted to Know Why.
When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...
www.propublica.org
September 10, 2026 at 1:15 AM
Revlimid has its origin in a pill that cost patients $7.50 each.
Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture.
(Published May 2025)
Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture.
(Published May 2025)
Reposted by Jota
Pancreatic cancer is one of the deadliest types of cancer.
A new treatment nearly doubled the survival time for patients and had fewer severe side effects than other alternatives. https://to.pbs.org/4gotcOJ
A new treatment nearly doubled the survival time for patients and had fewer severe side effects than other alternatives. https://to.pbs.org/4gotcOJ
Groundbreaking treatments and vaccines offer hope in fight against cancer
There have been several promising developments lately in cancer research and treatment, including a new drug approved by the FDA this week for advanced pancreatic cancer. William Brangham reports.
to.pbs.org
September 7, 2026 at 5:03 PM
Pancreatic cancer is one of the deadliest types of cancer.
A new treatment nearly doubled the survival time for patients and had fewer severe side effects than other alternatives. https://to.pbs.org/4gotcOJ
A new treatment nearly doubled the survival time for patients and had fewer severe side effects than other alternatives. https://to.pbs.org/4gotcOJ
Estoy leyendo "Salud mental infanto-adolescente: desigualdad que el promedio no deja ver" en Cooperativa
September 6, 2026 at 10:21 PM
Estoy leyendo "Salud mental infanto-adolescente: desigualdad que el promedio no deja ver" en Cooperativa